In Vitro Antifungal Susceptibilities of *Sporothrix schenckii* in Two Growth Phases

Luciana Trilles, Belkys Fernández-Torres, Márcia dos Santos Lazéra, Bodo Wanke, Armando de Oliveira Schubach, Rodrigo de Almeida Paes, Isabel Inza, and Josep Guarro*

Serviço de Micología Médica, Instituto de Pesquisa Clínica Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil, and Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain

Received 28 December 2004/Returned for modification 5 January 2005/Accepted 5 June 2005

We have determined the antifungal susceptibilities of 34 clinical isolates of the dimorphic fungus *Sporothrix schenckii* to 11 drugs using a microdilution method. In general, the type of growth phase (mycelial or yeast) and the temperature of incubation (30 or 35°C) exerted a significant influence on the MICs.

*Sporothrix schenckii* is a thermally dimorphic fungus and the most common agent of subcutaneous mycosis in Latin America (2, 12). Pulmonary and disseminated sporotrichosis can also occur when *S. schenckii* conidia are inhaled (16). Itraconazole (ITC) is generally used for the treatment of lymphocutaneous infection (3, 13, 21), while amphotericin B (AMB) is indicated for severe infections or when ITC therapy fails (9). Although these drugs are generally effective, the long duration of therapy and the strong toxicity of AMB make it necessary to explore new alternatives for the treatment of severe infections.

The infective form of sporotrichosis is the yeast phase (Y). However, the reference methods for in vitro antifungal susceptibility testing propose conditions only for the testing of its mycelial phase (M) (19). Testing of Y requires the use of other conditions. Although the optimal temperature for the in vitro growth of *S. schenckii* ranges from 25°C to 30°C (7), the reference method recommends a temperature of incubation of 35°C. The few studies that have determined the in vitro antifungal susceptibility of *S. schenckii* have used as the inoculum a mixture of hyphae and conidia obtained from its M (8, 14).

We have evaluated the in vitro activities of 11 antifungal agents against clinical isolates of *S. schenckii* in order to determine if the form of growth and temperature of incubation can influence the MICs.

A total of 34 isolates were tested (18 were from patients with disseminated sporotrichosis, 15 were from patients with the lymphocutaneous or cutaneous form of infection, and 1 was from domestic dust). *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258 were used as control strains.

The following 11 antifungal agents were tested by a microdilution method (18, 19): albaconazole (ABC), AMB, eberconazole (EBC), flucytosine (5FC), fluconazole (FLC), ITC, ketocanazole (KTC), micafungin (MFG), ravuconazole (RVC), terbinafine (TRB), and voriconazole (VRC).

To convert *S. schenckii* into Y, the procedure was performed as described by Ghosh et al. (7). Mycelial cultures grown on potato dextrose agar (PDA) were subcultured on brain heart infusion agar supplemented with 5% defibrinated sheep blood at 37°C for approximately 6 to 9 days. Several successive passages were done to achieve Y. The suspensions were adjusted hemacytometrically, diluted 1:50, and further diluted 1:20 in RPMI to obtain double the final inoculum, which ranged from $1.0 \times 10^5$ to $5.0 \times 10^5$ CFU/ml. This inoculum was similar to that used by Nakai et al. (17). The size of the inoculum was verified by determination of quantitative colony counts on

![FIG. 1. Distribution of the ITC MICs, tested at 35°C, against the yeast (A) and the mycelial (B) phases of *S. schenckii* from patients with cutaneous and disseminated sporotrichosis. Geometric means for panel A, disseminated, 2.13 μg/ml; cutaneous, 0.63 μg/ml ($P = 0.035$, independent samples $t$ test); geometric means for panel B, disseminated, 2.26 μg/ml; cutaneous, 1 μg/ml ($P = 0.402$, Mann-Whitney U test). $P$ values refer to differences between the MICs for isolates from disseminated and cutaneous cases. Statistical significance was assessed at a $P$ value of $<0.05$.](image-url)
and VRC. Significant differences were also observed when the
obtained with Y at the same temperature for EBC, ITC, TRB,
showed a lower MIC at 30°C than at 35°C. The MICs obtained with the two forms of growth could be
compared, with M, there were no differences in the activities of
the isolates from disseminated infections were less sus-
cient to ITC than those from localized infections. This is
relevant because, as mentioned above, ITC is a drug recom-
mended for the treatment of sporotrichosis (3, 13, 21). These
differences were statistically significant when Y was tested. In
contrast, with M, there were no differences in the activities of
ITC against the two forms of sporotrichosis (Fig. 1). These
data correlate with the high frequency of therapeutic failure in
the cases of disseminated sporotrichosis observed in our Bra-
zilian institution (Fundação Oswaldo Cruz [FIOCRUZ]). This
suggests that a possibly different genetic species of S. schenckii,
hardly distinguishable morphologically, was responsible for the
MICs for M at 30°C and those for Y at 35°C were compared.
The MICs were significantly lower for Y at 35°C than for M at
30°C for ABC, AMB, EBC, TRB, and VRC. The only exception
was VRC, which showed a lower MIC for M at 30°C than for
Y at 35°C (Table 1).
All the azoles with the exception of EBC showed geometric
mean (GM) MFCs of >16 μg/ml against both growth forms.
For the azoles, the differences between the MFCs and the
MICs were notable (3 or more dilutions) for the two forms of
growth. This seems to indicate that the azoles tested have fungistatic activity against this fungus. In the case of AMB and
TRB, the differences between the MFCs and the MICs were
less than 2 dilutions. No statistically significant differences
were found between the GM MFCs for Y at 35°C and M at
35°C for any antifungal agent (Table 2).
One of the most interesting findings of the present study was
that the isolates from disseminated infections were less sus-
cient to ITC than those from localized infections. This is
relevant because, as mentioned above, ITC is a drug recom-
mended for the treatment of sporotrichosis (3, 13, 21). These
differences were statistically significant when Y was tested. In
contrast, with M, there were no differences in the activities of
ITC against the two forms of sporotrichosis (Fig. 1). These
data correlate with the high frequency of therapeutic failure in
the cases of disseminated sporotrichosis observed in our Bra-
zilian institution (Fundação Oswaldo Cruz [FIOCRUZ]). This
suggests that a possibly different genetic species of S. schenckii,
hardly distinguishable morphologically, was responsible for the

<table>
<thead>
<tr>
<th>Growth phase/temp (°C) (no. of isolates tested) and parameter</th>
<th>ABC</th>
<th>AMB</th>
<th>EBC</th>
<th>ITC</th>
<th>5FC</th>
<th>FLC</th>
<th>MFG</th>
<th>KTC</th>
<th>RVC</th>
<th>TRB</th>
<th>VRC</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/35 (34) Range GM</td>
<td>0.125–16 2.95&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1–4</td>
<td>0.06–4</td>
<td>0.25–16</td>
<td>16–64</td>
<td>&gt;64</td>
<td>&gt;128</td>
<td>0.03–16</td>
<td>1–16</td>
<td>0.125–4</td>
<td>0.5–16</td>
</tr>
<tr>
<td>M/30 (34) Range GM</td>
<td>0.5–16 7.30&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1–16</td>
<td>0.06–16</td>
<td>0.125–16</td>
<td>64–64</td>
<td>&gt;64</td>
<td>&gt;128</td>
<td>0.125–2</td>
<td>0.125–8</td>
<td>1–4</td>
<td>1–16</td>
</tr>
<tr>
<td>Y/35 (24) Range GM</td>
<td>0.06–8 2.37&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1–4</td>
<td>0.03–2</td>
<td>0.25–16</td>
<td>16–64</td>
<td>16–64</td>
<td>&gt;128</td>
<td>0.125–4</td>
<td>0.25–8</td>
<td>0.06–1</td>
<td>2–16</td>
</tr>
</tbody>
</table>

<sup>a</sup> Statistically significant with respect to the geometric mean MIC in the mycelial growth phase at 30°C (<i>P</i> < 0.05; Student’s <i>t</i> test, paired).
<sup>b</sup> Statistically significant with respect to the geometric mean MIC in the yeast growth phase at 35°C (<i>P</i> < 0.05; Student’s <i>t</i> test, paired).
<sup>c</sup> Statistically significant with respect to the geometric mean MIC in the mycelial growth phase at 30°C (<i>P</i> < 0.05; Student’s <i>t</i> test, paired).

**TABLE 2. MFCs of eight antifungal agents against the two phases of growth of Sporothrix schenckii**

<table>
<thead>
<tr>
<th>Growth phase/temp (°C) (no. of isolates tested) and parameter</th>
<th>ABC</th>
<th>AMB</th>
<th>EBC</th>
<th>ITC</th>
<th>5FC</th>
<th>FLC</th>
<th>MFG</th>
<th>KTC</th>
<th>RVC</th>
<th>TRB</th>
<th>VRC</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/35 (34) Range GM</td>
<td>0.125–16 1–16</td>
<td>0.125–16</td>
<td>4–16</td>
<td>4–16</td>
<td>1–16</td>
<td>1–16</td>
<td>4–16</td>
<td>0.125–16</td>
<td>1–16</td>
<td>2.21</td>
<td>16</td>
</tr>
<tr>
<td>Y/35 (24) Range GM</td>
<td>0.125–16 1–16</td>
<td>0.03–16</td>
<td>1–16</td>
<td>2–16</td>
<td>16–16</td>
<td>0.25–16</td>
<td>4–16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> MFCs for 5FC, FLC, and MFG were not determined (MICs, >64 μg/ml) (<i>P</i> < 0.05, Student’s <i>t</i> test, paired).
different clinical manifestations, as happens with other pathogenic fungi (Trichosporon, Malassezia, etc.). This is an interesting topic for further study. FLC is considered the second-line treatment for sporotrichosis (4). In spite of the poor activity that this drug has shown in this and other studies (6, 17), its clinical efficacy has been estimated to be 71% for cases of lymphocutaneous infection (10). KTC has shown poor efficacy against different forms of sporotrichosis (13). However, our in vitro results agree with those obtained by Shadowy et al. (20), who also found that this drug has very good activity in vitro. In our study, in agreement with Kohler et al. (11), who used a macrodilution method, TRB has also shown good activity, mainly when Y was tested. Although a few reports on the clinical efficacy of TRB exist (1, 15), the data are still too scarce to recommend its use as a possible alternative treatment. Our data seem to indicate that one of the most promising drugs for the treatment of mold infections, VRC, is not a good candidate for sporotrichosis management. McGinnis et al. (14) and Johnson et al. (8) also reported high MICs for VRC when a mixture of hyphae and conidia was used as the inoculum. EBC is a topical antifungal agent that has been shown to have excellent activity both in vitro and in vivo against yeasts and dermatophytes (5). In this study, this drug was very active against the two forms of growth of S. schenckii. In conclusion, our data demonstrate that the growth form and temperature of incubation considerably influence the antifungal susceptibility of S. schenckii. Further in vivo studies are required to prove which growth phase and temperature of incubation are the most predictive of the clinical outcome.

This work was partially supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro-FAPERJ, Rio de Janeiro, Brazil, and by a grant from Fundação de Investigaciones Sanitarias from the Ministerio de Sanidad y Consumo of Spain (PI 020114).

REFERENCES